Revelation Biosciences, Inc. (REVB)
NASDAQ: REVB · Real-Time Price · USD
0.835
-0.006 (-0.65%)
At close: Oct 25, 2024, 4:00 PM
0.830
-0.005 (-0.54%)
After-hours: Oct 25, 2024, 5:27 PM EDT
Revelation Biosciences Employees
Revelation Biosciences had 9 employees as of December 31, 2023. The number of employees increased by 3 or 50.00% compared to the previous year.
Employees
9
Change (1Y)
3
Growth (1Y)
50.00%
Revenue / Employee
n/a
Profits / Employee
-$1,766,948
Market Cap
1.37M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 9 | 3 | 50.00% |
| Dec 31, 2022 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Aditxt | 47 |
| TC Biopharm (Holdings) | 41 |
| LogicMark | 27 |
| Altamira Therapeutics | 10 |
| Bluejay Diagnostics | 10 |
| Tivic Health Systems | 9 |
| PainReform | 7 |
| 60 Degrees Pharmaceuticals | 3 |
REVB News
- 4 weeks ago - Revelation Biosciences' Gemini Induces Dose Dependent Significant Increases in IL-10 - Business Wire
- 2 months ago - Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds - Business Wire
- 2 months ago - Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024 - Business Wire
- 4 months ago - Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity - Business Wire
- 4 months ago - Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini - Business Wire
- 6 months ago - Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024 - Business Wire
- 7 months ago - Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023 - Business Wire
- 8 months ago - Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024) - Business Wire